Background:
The drug olaparib may stop cancer cells from fixing damage to their deoxyribonucleic acid
(DNA). It has been approved to treat certain cancers in people that were born with a mutation
in the breast cancer (BRCA) gene. It has not been approved for treating mesothelioma. But
some people with mesothelioma have mutations in a gene, BRCA1 Associated Protein 1 (BAP1)
related to BRCA. Researchers want to see if olaparib can work in patients with mutations in
this gene. They also want to see if works on mutations in other genes or patients without any
mutations. They want to see if olaparib causes mesothelioma tumors to shrink.
Objective:
To study the effect of olaparib on mesothelioma.
Eligibility:
People ages 18 and older with malignant mesothelioma that has already been treated
Design:
Participants will be screened with
Sample of tumor tissue or fluid
Medical history
Physical exam
Blood, heart, and urine tests
Scans and x-rays
Participants will give blood and tissue samples. These will be genetically tested.
The study will be done in 21-day cycles.
Participants will take tables of the study drug 2 times each day. They will get information
on what food and drugs to avoid during the study. They will get information about birth
control. They will keep a diary of doses and symptoms.
Participants will have blood and urine tests and scans every few weeks.
Participants will be told any important genetic testing results.
Participants will stay in the study until their disease gets worse or the participant or
their doctor chooses to stop it.
About 30 days after stopping the study drug, participants will have a follow-up visit. They
will have a medical history, physical exam, blood tests, and scans.
Some participants will continue to have scans every 6 weeks.
...